drug
deferiprone
Marketedupdated 3mo agoby Chiesi USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(1)
Trials studying deferiprone
- phase2Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
- phase2Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
- phase2Study of Parkinson's Early Stage With Deferiprone
- phase4Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
- phase4Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 30, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Oct 25, 2038formulationUS 10780055
- Oct 25, 2038formulationUS 10940115
- Oct 25, 2038formulationUS 10940116
- Oct 25, 2038method-of-use (U-3083)US 11357731
- Oct 25, 2038formulationUS 11458103
- Oct 25, 2038method-of-use (U-3083)US 11723874
- Oct 26, 2029formulationUS 87031563.2y
- Oct 26, 2029formulationUS 87031563.2y
FDA exclusivities (15)
- Apr 30, 2028ODE-417Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-420Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-421Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-417Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-420Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-421Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-417Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-418Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-419Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-417Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-418Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-419Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-417Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-420Orphan Drug (7y)1.7y
- Apr 30, 2028ODE-421Orphan Drug (7y)1.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that